Opendata, web and dolomites


The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Total Cost €


EC-Contrib. €






 N-IF project word cloud

Explore the words cloud of the N-IF project. It provides you a very rough idea of what is the project "N-IF" about.

good    hampered    disease    2015    translate    huge    commercializing    reductions    drugs    health    ultimate    experimental    animal    tests    weeks    fibrotic    human    exhibits    bio    efficacy    preclinical    inflammation    spontaneously    reproducibility    preceded    efficient    doors    course    despite    inficure    swedish    industry    prevalence    enlarging    induce    consuming    progression    liver    model    robustness    chronic    pathology    primary    segments    life    develops    diseases    clients    pulmonary    conduct    mouse    experiment    date    market    population    inflammatory    100    humans    resemble    demanded    opening    shorten    acquired    models    drug    world    proprietary    renal    animals    science    protocols    founded    50    validation    eliminates    intensive    mice    25    lack    prepare    minimize    time    company    labour    decrease    pharmaceutical    feasibility    anti    nash    technically    fibrosis    therapies    pipeline    validated   

Project "N-IF" data sheet

The following table provides information about the project.


Organization address
address: TVISTEVAGEN 48C
city: UMEA
postcode: 907 36
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INFICURE BIO AKTIEBOLAG SE (UMEA) coordinator 50˙000.00


 Project objective

InfiCure Bio is a Swedish Life Science company that was founded in 2015 with the primary objective of developing and commercializing a proprietary model for preclinical efficacy testing of anti-inflammatory and anti-fibrotic drugs. Our key product, the N-IF mouse, is a unique animal model that spontaneously develops fibrosis which is preceded by chronic inflammation and exhibits the same course of fibrotic disease progression as in humans, a unique feature that has been an ultimate need demanded by the pharmaceutical industry for many years.

There are no efficient therapies aimed against fibrotic diseases despite the high prevalence among the world population and the huge impact on human health. To date, drug development has been hampered due to the lack of good and reliable preclinical models that better resemble human fibrotic disease conditions. The N-IF mouse eliminates the problems of currently available animal models that are time-consuming, labour-intensive to induce fibrosis and have a low reproducibility. Its unique features will allow to shorten test protocols by 4-8 weeks, increase robustness of tests due to its 100% reproducibility and minimize the number of experimental animals needed. Reductions in experiment time and in mice numbers directly translate into a 25 - 50% decrease in the overall costs of preclinical testing of anti-fibrotic drugs. We have already technically validated the N-IF mouse as a model for liver fibrosis and have acquired two clients. The objective of the Phase 1 project is to conduct a feasibility study and prepare for further validation studies of the mouse model in order to establish the pathology of NASH, renal and pulmonary fibrosis that will be conducted as part of Phase 2, enlarging our pipeline models for fibrotic diseases and opening doors to new segments of the fibrotic diseases market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "N-IF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "N-IF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  


Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More